Related Experiment Videos
Chimeric antibody: potential applications for drug delivery and immunotherapy
1UCLA, Department of Microbiology 90024.
Biotherapy (Dordrecht, Netherlands)
|January 1, 1991
Summary
Genetically engineered antibodies offer new cancer therapy options. By joining growth factors to antibodies, researchers aim to improve targeted drug delivery and overcome limitations of current treatments.
Area of Science:
- Biotechnology
- Immunology
- Cancer Research
Background:
- Antibodies show promise for targeting cancer cells.
- Monoclonal antibodies have limitations as anti-cancer drugs.
- Transfectomas offer a method to engineer antibodies.
Purpose of the Study:
- To engineer multi-functional chimeric antibodies for improved cancer therapy.
- To overcome limitations of current antibody-based cancer treatments.
- To create novel immunotherapeutic molecules.
Main Methods:
- Utilizing transfectomas for gene transfection into lymphoid cells.
- Creating genetically engineered antibodies by joining non-immunoglobulin sequences to antibody sequences.
- Developing chimeric antibodies with growth factors linked to specific binding sites.
Main Results:
- Demonstrated the creation of multi-functional chimeric antibodies.
- Proposed a method for targeting therapy to malignant cells.
- Suggested potential for transcytosis across the blood-brain barrier via growth factor receptors.
Conclusions:
- Genetically engineered chimeric antibodies represent a novel class of immunotherapeutic agents.
- These novel antibodies may enhance targeted cancer therapy and drug delivery.
- The approach offers a way to overcome inherent limitations of traditional monoclonal antibodies.